Sangamo 2025 net loss $122.9M; cash only $20.9M; Fabry BLA rolling submission ongoing

SANGAMO THERAPEUTICS, INC

Consolidated 2025 net loss $122.9M ($0.44/sh); Q4 loss $37.4M ($0.11/sh).
Revenue in 2025 fell to $39.6M from $57.8M; Q4 revenue $14.2M up from $7.6M, driven by Pfizer and Lilly collaborations.
Cash and equivalents $20.9M as of Dec 31; expects funding into Q3 2026 after recent $25M offering and other receipts.
Rolling BLA submission to FDA for ST-920 (Fabry gene therapy) in progress; CMC module expected summer 2026 subject to funding.
Neurology pipeline advancing: Phase 1/2 STAND study for ST-503 in chronic pain with six sites activated; Eli Lilly capsid license added.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANGAMO THERAPEUTICS, INC reported fourth quarter ended December 31, 2025 results: revenue $14.2 million, net income $37.4 million, EPS $0.11 per share.

Period: fourth quarter ended December 31, 2025
Revenue: $14.2 million
Net income: $37.4 million
EPS: $0.11 per share
Result: reported results

Exact text from the filing

to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANGAMO THERAPEUTICS, INC reported year ended December 31, 2025 results: revenue $39.6 million, net income $122.9 million, EPS $0.44 per share.

Period: year ended December 31, 2025
Revenue: $39.6 million
Net income: $122.9 million
EPS: $0.44 per share
Result: reported results

Exact text from the filing

For the year ended December 31, 2025, consolidated net loss was $122.9 million, or $0.44 per share, compared to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s exercise of its option to obtain a license pursuant to the terms of the 2008 licensing agreement for certain zinc finger modified cell lines, an increase of $1.0 million in revenue relating to our collaboration agreement with Astellas, and $0.4 million in revenue from research services relating to our capsid license agreement with Lilly, partially offset by $0.8 million in revenue relating to our collaboration agreement with Genentech recognized in 2024. Revenues were $39.6 million in 2025, compared to $57.8 million in 2024. The

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-26-022006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.